1. Academic Validation
  2. Rapid Plastic Deformation of Cancer Cells Correlates with High Metastatic Potential

Rapid Plastic Deformation of Cancer Cells Correlates with High Metastatic Potential

  • Adv Healthc Mater. 2022 Apr;11(8):e2101657. doi: 10.1002/adhm.202101657.
Zishen Yan 1 2 Xingyu Xia 1 2 William C Cho 3 Dennis W Au 3 Xueying Shao 1 Chao Fang 1 2 Ye Tian 1 2 Yuan Lin 1 2 4
Affiliations

Affiliations

  • 1 Department of Mechanical Engineering, The University of Hong Kong, Hong Kong, China.
  • 2 HKU-Shenzhen Institute of Research and Innovation (HKU-SIRI), Shenzhen, Guangdong, China.
  • 3 Department of Clinical Oncology, Queen Elizabeth Hospital, Hong Kong SAR, China.
  • 4 Advanced Biomedical Instrumentation Centre, Hong Kong Science Park, Shatin, New Territories, Hong Kong.
Abstract

Metastasis plays a crucial role in tumor development, however, lack of quantitative methods to characterize the capability of cells to undergo plastic deformations has hindered the understanding of this important process. Here, a microfluidic system capable of imposing precisely controlled cyclic deformation on cells and therefore probing their viscoelastic and plastic characteristics is developed. Interestingly, it is found that significant plastic strain can accumulate rapidly in highly invasive Cancer cell lines and circulating tumor cells (CTCs) from late-stage lung Cancer patients with a characteristic time of a few seconds. In constrast, very little irreversible deformation is observed in the less invasive cell lines and CTCs from early-stage lung Cancer patients, highlighting the potential of using the plastic response of cells as a novel marker in future Cancer study. Furthermore, author showed that the observed irreversible deformation should originate mainly from Cytoskeleton damage, rather than plasticity of the cell nucleus.

Keywords

cell plasticity; circulating tumor cells; cytoskeleton damage; metastatic potential; non-small cell lung cancer.

Figures
Products
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • HY-13813
    99.64%, Myosin II 抑制剂